Loading…
Loading…
MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Thursday with a session volume of 4.20 million compared to the average volume of 1.494 million, according to Benzinga Pro data.
MoonLake Immunotherapeutics offers a compelling investment case despite sonelokimab's mixed clinical results, focusing on regulatory progress and commercial viability. MLTX can file for HS approval without another major trial, accelerating potential revenue and reducing dilution risk, with cash runway projected through mid-2028. Sonelokimab's durability and differentiated nanobody structure support its commercial potential, but competitive execution and access will be key to market success.
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders acquired 2,707 call options on the company. This is an increase of 142% compared to the typical daily volume of 1,118 call options. Insider Transactions at MoonLake Immunotherapeutics In related news, insider Kristian Reich sold
MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving adults with an inflammatory disease who had not previously received biologic medicines.
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis Meaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS Blinded safety analysis suggests a profile consistent with previous studies and no new safety signals were identified, reinforcing sonelokimab's potential to become a leading treatment option for patients living with psoriatic arthritis, and enabling MoonLake's entry into another multi-billion dollar indication The IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027 whereas the IZAR-2 trial (a trial in TNF-refractory patients) is expected to complete enrollment in Q3 2026 MoonLake ended the second quarter with $ 537.0 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital ZUG, Switzerland, August 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis (PsA) and reported second quarter 2026 financial results. IZAR-1 Phase 3 trial Week 16 positive topline results The IZAR Phase 3 program consists of two registrational global randomized, double-blind trials, IZAR-1 and IZAR-2, designed to evaluate the efficacy and safety of sonelokimab in adults with active psoriatic arthritis (PsA).
Arrowstreet Capital Limited Partnership bought a new stake in MoonLake Immunotherapeutics (NASDAQ: MLTX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 70,140 shares of the company's stock, valued at approximately $1,307,000. Arrowstreet Capital Limited Partnership owned about 0.10%
The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.